Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

INGN-225 to be studied for advanced breast cancer in phase I/II trial

Dec. 11, 2003

Interim results from phase II studies of HuMax-CD4 for CTCL

Dec. 11, 2003

Encouraging outcomes for Rituxan phase II and III trials

Dec. 11, 2003

hTERT-based vaccine approaches to breast cancer

Dec. 10, 2003

MLN-2704 granted fast track designation

Dec. 9, 2003

Antitumor effects of the HLA-DR-specific MAb 1D09C3 shown in vitro and in vivo

Dec. 9, 2003

Cetuximab enhances antitumor effects of cisplatin in late-stage clinical trial

Nov. 27, 2003

Medarex given go-ahead to begin phase I/II trial of MDX-214

Nov. 26, 2003

FDA lifts partial clinical hold on phase III trials of Oncophage

Nov. 26, 2003

Shionogi describes GM-CSF-like compounds with potential in cancer and neutropenia

Nov. 25, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...